



## Utilization of galactooligosaccharides by *Bifidobacterium longum* subsp. *infantis* isolates

Daniel Garrido<sup>a,d</sup>, Santiago Ruiz-Moyano<sup>a,d</sup>, Rogelio Jimenez-Espinoza<sup>c</sup>, Hyun-Ju Eom<sup>b,d</sup>, David E. Block<sup>b,c</sup>, David A. Mills<sup>a,b,d,\*</sup>

<sup>a</sup> Department of Food Science and Technology, University of California Davis, 1 Shields Ave., Davis, CA 95616, USA

<sup>b</sup> Department of Viticulture and Enology, University of California Davis, 1 Shields Ave., Davis, CA 95616, USA

<sup>c</sup> Department of Chemical Engineering, University of California Davis, 1 Shields Ave., Davis, CA 95616, USA

<sup>d</sup> Foods for Health Institute, University of California Davis, 1 Shields Ave., Davis, CA 95616, USA

### ARTICLE INFO

#### Article history:

Received 19 September 2012

Received in revised form

5 October 2012

Accepted 5 October 2012

Available online 22 October 2012

#### Keywords:

*Bifidobacterium longum* subsp. *infantis*

Prebiotics

Galactooligosaccharides

β-Galactosidase

### ABSTRACT

Prebiotics are non-digestible substrates that stimulate the growth of beneficial microbial populations in the intestine, especially *Bifidobacterium* species. Among them, fructo- and galacto-oligosaccharides are commonly used in the food industry, especially as a supplement for infant formulas. Mechanistic details on the enrichment of bifidobacteria by these prebiotics are important to understand the effects of these dietary interventions. In this study the consumption of galactooligosaccharides was studied for 22 isolates of *Bifidobacterium longum* subsp. *infantis*, one of the most representative species in the infant gut microbiota. In general all isolates showed a vigorous growth on these oligosaccharides, but consumption of larger galactooligosaccharides was variable. *Bifidobacterium infantis* ATCC 15697 has five genes encoding β-galactosidases, and three of them were induced during bacterial growth on commercial galactooligosaccharides. Recombinant β-galactosidases from *B. infantis* ATCC 15697 displayed different preferences for β-galactosides such as 4' and 6'-galactobiose, and four β-galactosidases in this strain released monosaccharides from galactooligosaccharides. Finally, we determined the amounts of short chain fatty acids produced by strain ATCC 15697 after growth on different prebiotics. We observed that biomass and product yields of substrate were higher for lactose and galactooligosaccharides, but the amount of acids produced per cell was larger after growth on human milk oligosaccharides. These results provide a molecular basis for galactooligosaccharide consumption in *B. infantis*, and also represent evidence for physiological differences in the metabolism of prebiotics that might have a differential impact on the host.

© 2012 Elsevier Ltd. All rights reserved.

### 1. Introduction

The *Bifidobacterium* genus is composed of Gram-positive strictly anaerobic rods, which are common inhabitants of the intestinal tract of humans (Lee and O'Sullivan, 2010). They are dominant in the infant gut microbiota, especially in breast-fed infants (Yatsunenkov et al., 2012), where they can represent up to the 90% of the total bacteria in this environment (Boesten et al., 2011).

**Abbreviations:** GOS, galactooligosaccharides; HMO, human milk oligosaccharides; FOS, fructooligosaccharides; LNT, lacto-N-tetraose; SCFA, short chain fatty acids.

\* Corresponding author. Department of Viticulture and Enology, University of California Davis, 1 Shields Ave., Davis, CA 95616, USA. Tel.: +1 530 754 7821; fax: +1 530 752 0382.

E-mail address: [damills@ucdavis.edu](mailto:damills@ucdavis.edu) (D.A. Mills).

Bifidobacteria still represent a significant proportion of the adult gut microbiota (Eckburg et al., 2005), however different species can be found in both environments (Mangin et al., 2006; Roger et al., 2010).

Bifidobacteria show remarkable adaptations to use and metabolize complex oligosaccharides as a carbon and energy source (Lee and O'Sullivan, 2010). In breast-fed infants, the main carbon sources available for the developing intestinal microbiota are human milk oligosaccharides (HMO; (Kunz et al., 2000)) and certain bifidobacteria can gain access to N- and O-glycans in milk proteins or mucins (Garrido et al., 2012b; Ruas-Madiedo et al., 2008). Only a few bacterial species have been shown to use these substrates (Marcobal et al., 2010), and the molecular mechanisms involved in HMO consumption in bifidobacteria are beginning to be understood (Garrido et al., 2012a). In adults, diet delivers the intestinal microbiota a great variety of oligo- and polysaccharides, which are

resistant to enzymatic degradation in the intestinal lumen and therefore reach distal portions of the intestine. Different *Bifidobacterium* species are capable of metabolizing complex oligosaccharides usually from plant origin such as cellodextrins and amyloses (Pokusaeva et al., 2011), raffinose (Dinoto et al., 2006), arabinooligosaccharides (Lagaert et al., 2010; Van Laere et al., 1997), xylooligosaccharides (Gilad et al., 2010), fructooligosaccharides and inulin (Omori et al., 2010; Perrin et al., 2001; Rossi et al., 2005), galactans and galactooligosaccharides (GOS; (Barboza et al., 2009; Goulas et al., 2009a; Hinz et al., 2005; O'Connell Motherway et al., 2011)) among several others.

Several infant formulas are supplemented with FOS and GOS with the aim of replicating some of the beneficial effects of human milk, in special its bifidogenic effect (Bakker-Zierikzee et al., 2005; Brunser et al., 2006). GOS are synthetically produced by microbial  $\beta$ -galactosidases (Gosling et al., 2010), which under specific conditions can perform transglycosylation reactions with lactose as the starting material. These enzymes are widespread in bifidobacteria, and some of them have remarkable yields in GOS synthesis (Hinz et al., 2004; Hung and Lee, 2002; Rabiou et al., 2001). GOS can have a degree of polymerization (DP) between 3 and 15 (Barboza et al., 2009) and are composed of galactose oligomers in  $\beta$ 1-3/4/6 linkages with a terminal glucose residue (Coulter et al., 2009; Gosling et al., 2010). These substrates have been extensively studied for their prebiotic status, promoting the growth of beneficial microorganisms such as bifidobacteria and lactobacilli (Andersen et al., 2011; Davis et al., 2011), therefore providing putative health benefits (Gibson et al., 2004). GOS structures resemble galactan chains found in plant oligosaccharides abundant in adult diets, which might explain how these microorganisms consume GOS.

The mechanisms by which infant bifidobacteria are enriched by these prebiotics probably include oligosaccharide transporters and  $\beta$ -galactosidases specific for these substrates. In *Bifidobacterium longum* subsp. *infantis* ATCC 15697, two genes encoding solute-binding proteins (SBPs) from ABC transporters were specifically induced during growth on GOS (Garrido et al., 2011).  $\beta$ -galactosidases are widespread enzymes in bifidobacteria, and they display diverse substrate specificities (Goulas et al., 2009b). Two  $\beta$ -galactosidases in *Bifidobacterium infantis* HL96 have been previously studied (Hung and Lee, 2002; Hung et al., 2001) regarding their transglycosylation properties, and recently two  $\beta$ -galactosidases in the strain ATCC 15697 were shown to be active on different linkages found in HMO (Yoshida et al., 2012), and their activity likely complements  $\beta$ -hexosaminidases in this bacterium (Garrido et al., 2012c). Of increasing interest are also the metabolites produced after bifidobacterial fermentation of sugars, especially short chain fatty acids (SCFA) such as acetate and lactate as they represent one of the main protective mechanisms of bifidobacteria for its host (Fukuda et al., 2011). In this study we have characterized the consumption of GOS in a panel of *B. infantis* isolates from infant feces, and we further investigated the mechanisms involved in GOS degradation and metabolism in the type strain ATCC 15697.

## 2. Materials and methods

### 2.1. Microorganisms and media

Strains used in this study (Supplementary Table 1), were obtained from the American Type Culture Collection (Manassas, VA), and the University of California Davis Viticulture and Enology Culture Collection (Davis, CA). De Mann, Rogose and Sharp (MRS) broth supplemented with 0.05% w/v L-cysteine (Sigma–Aldrich, St. Louis, MO) was used for routine growth of *B. infantis* under anaerobic conditions (Coy Laboratory Products, Grass Lake, MI) at

hydrogen, and 90% nitrogen. Chemically competent *Escherichia coli* BL21 Star and Top10 cells were obtained from Invitrogen (Carlsbad, CA), and transformants were cultured at 37 °C in Luria Broth with 50  $\mu$ g/ml carbenicillin (Teknova, Hollister CA) when necessary.

### 2.2. Consumption of GOS by *B. infantis* isolates

*Bifidobacterium* isolates in Supplementary Table 1 were grown overnight in MRS and inoculated at 5% in modified MRS (mMRS), containing no carbon source, and supplemented with 0.05% cysteine (Sigma) and 0.5% commercial GOS (Purimune, GTC Nutrition, Golden, CO) or 0.5% lactose as a growth control. Growth was monitored using a PowerWave microplate spectrophotometer (BioTek Instruments, Winoosky, VT) at 37 °C for 48 h, reading absorbance at 600 nm. Each experiment was done in triplicate, and controls with no carbon source and no bacteria were subtracted from growth values. Aliquots of the reactions (1  $\mu$ l) were spotted in TLC Silica gel plates (Sigma). A mixture of n-propanol, acetic acid and water in a 2:1:1 ratio was used as solvent. Plates were dried and sprayed with 0.5%  $\alpha$ -naphthol and 5% H<sub>2</sub>SO<sub>4</sub> in ethanol, and developed at 150 °C for 10 min.

### 2.3. Gene expression analysis

For RNA extraction, *B. infantis* ATCC 15697 was grown on the chemically defined media Zhang-Block-Mills 1 (ZMB-1; (Zhang et al., 2009)) to which 2% w/v of glucose (Sigma), lactose (Sigma), GOS (GTC nutrition) or purified HMO (Ward et al., 2006) were added. Growth was monitored in a plate reader as described above. Cells at exponential phase were pelleted at 12,000  $\times$  g for 2 min, resuspended in 1 ml of RNA later (Ambion, Austin, TX), stored at 4 °C overnight and then at –80 °C until use. RNA extraction was performed using the RNAqueous Ambion kit (Ambion) and cDNA was obtained from 10  $\mu$ g of RNA using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems). For the relative quantification of  $\beta$ -galactosidase and related genes, the Fast Sybr Green Master Mix (Applied Biosystems, Foster City, CA) was used, using the gene Blon\_0393, cysteinyl-tRNA synthetase, as the endogenous control (Parche et al., 2006). Reaction conditions were as recommended by manufacturer. Primer efficiency was normalized in each plate using standard curves. The Primer3 software was used for primer design (Supplementary Table 2), and the Q-gene software was used for relative quantification analysis.

### 2.4. $\beta$ -galactosidase gene cloning

*B. infantis* ATCC 15697 genomic DNA was obtained from overnight cultures on MRS, using the MasterPure Gram Positive DNA Purification Kit (Epicentre Biotechnologies, Madison, WI), following the manufacturer instructions. Primers used for PCR cloning are shown in Supplementary Table 2. PCR reactions contained 0.2 mM dNTPs (Fermentas, Glen Burnie, MD), 1 ng DNA, 0.5  $\mu$ M of each primer, and 2 U of Phusion DNA Polymerase (Finnzymes, Vantaa, Finland) in a 150  $\mu$ l final volume. PCR was performed in a Verity 96 well thermal cycler (Applied Biosystems), using the following program: initial denaturation at 98 °C for 2 min; 35 cycles of denaturation at 98 °C 30 s, annealing at 58 °C for 30 s, and extension at 72 °C 3 min; and a final extension at 72 °C for 7 min. PCR products were gel purified (Qiaquick Gel Extraction Kit, Qiagen, Valencia, CA) and cloned into pET101 using the Champion pET101 Directional TOPO Expression Kit (Invitrogen), following manufacturer instructions. Plasmids were transformed into BL21 star *E. coli* cells as well as Top10 cells for plasmid storage, and transformants were confirmed for the correct insert sequence by plasmid

## 2.5. Recombinant protein expression and purification

*E. coli* BL21 transformants were grown in 200 ml LB broth with 50 µg/ml carbenicillin in a shaker at 250 rpm (Innova-4000, New Brunswick Scientific, Edison, NJ) at 37 °C until cultures reached an O.D. of 0.6. Recombinant proteins were induced for 6 h with the following optimized conditions: 0.5 mM IPTG (USB) at 24 °C for Blon\_0268 and Blon\_2416; 0.5 mM IPTG at 28 °C for Blon\_2016; 1 mM IPTG at 24 °C (Blon\_2123) and 0.5 mM IPTG at 28 °C for Blon\_2334. Cultures were centrifuged in 50 ml falcon tubes at 4000 rpm in an Eppendorf 5804 centrifuge (Eppendorf, Hauppauge, NY) for 20 min at 4 °C, and pellets were kept at –80 °C until use. Cells were resuspended in Bugbuster Protein Extraction Reagent (EMD Chemicals), using 5 ml of the buffer for every 100 ml of culture. Lysozyme (Sigma Aldrich, 50 µl of 50 mg/ml stock), and DNase I (Roche Applied Sciences; 20 µl of 10,000 U stock) were added to help in bacterial lysis. The suspensions were vortexed and incubated for 10 min at room temperature, and centrifuged for 20 min at 13,200 rpm at 4 °C. Supernatants were recovered and applied to 1 ml Bio-Scale Mini Profinity IMAC cartridges, connected to an EP-1 Econo-pump (Bio-Rad, Hercules CA). Protein purification was performed as recommended by the manufacturer, but proteins were eluted using an imidazole gradient between 20 and 250 mM in the washing buffer. Recombinant β-galactosidases were checked for purity and correct molecular weight using 10% SDS-PAGE gels (Bio-Rad). Elution buffer was exchanged for PBS using Amicon Ultra-15 Centrifugal Filter Units, with a cut-off of 50 kDa (Millipore). Protein concentrations were determined using the Bio-Rad protein assay, with a standard curve using Bovine Serum Albumin (Sigma).

## 2.6. Determination of enzymatic kinetic parameters

Enzymatic assays were carried out using ortho-nitrophenyl-β-galactoside (ONPG; Sigma) at a concentration of 2 mg/ml and 1–10 µg of each recombinant enzyme. Optimum pH for each enzyme was determined using McIlvaine buffers, with values from 4.0 to 8.0. Reactions were performed in triplicate in 96 microwell plates, and contained 80 µl of each buffer, 15 µl of substrate, and 5 µl of enzyme. Reactions were incubated for 10 min at 37 °C, and stopped adding equal volumes of 1 M Na<sub>2</sub>CO<sub>3</sub>. Absorbance at 420 nm was determined using a Synergy 2 microplate reader (Biotek). For determination of optimum reaction temperatures, enzymatic assays were performed at optimum pH and at 4 °C, 30 °C, 37 °C, 45 °C, 55 °C and 65 °C. Relative activity was determined from OD<sub>420</sub> values. Kinetic constants were obtained using substrate concentrations in the range of 0.1–4 mM of ONPG and 1–100 µg of each enzyme. Reactions were performed at optimum pH and temperature, and times were preestablished to fall within the initial rate of reaction. Amounts of o-nitrophenol produced in each reaction were calculated from a standard curve and OD<sub>420</sub> values. Non-linear regression was used to determine  $K_m$  and  $V_{max}$ , fitting the experimental values to the Michaelis Menten equation, using the tool Solver on Microsoft Excel.

## 2.7. β-galactosidase substrate specificity determination

Recombinant enzymes were coinubated in phosphate buffer and 2 µg of the following substrates at their optimum pH and temperatures: D-lactose (Sigma), 3' galactosyl lactose (Carbosynth, Berkshire UK), Galβ1-4Gal (4' galactobiose; V-labs, Covington, LA), Galβ1-6Gal (6' galactobiose; V-labs), and 10 µg of commercial GOS (GTC Nutrition). Reactions were carried out in 10 µl for the specified times at 37 °C, and inactivated at 95 °C for 5 min. 1 µl of each

## 2.8. Evaluation of relative affinities of β-galactosidases

Equimolar concentrations (0.2 mM) of ONPG (Sigma), lactose (Sigma), 4' galactobiose (V-labs), 6' galactobiose (V-labs), 3' galactosyl lactose (Carbosynth, UK) and lacto-N-tetraose (V-labs) were coinubated with the same amount (1–20 µg) of each of the five recombinant β-galactosidases for 10 min at their optimum temperatures and pH in McIlvaine buffer in a 10 µl volume. Reactions were inactivated by incubation at 95 °C for 5 min. The Galactose Assay Kit (Biovision, Mountain View CA) was used to quantify galactose concentrations present in each sample, following the manufacturer instructions. Fluorescence was quantified using a standard curve in a Synergy 2 microplate reader. Values were normalized considering the amount of galactose released from ONPG as 100%.

## 2.9. Production of SCFA by *B. infantis* ATCC 15697

The production of acetate, lactate and formate by *B. infantis* was tested on seven different substrates: glucose (Sigma), lactose, HMO, LNT (V-labs), GOS, FOS (rafitlose Synergy 1, Orafti, Malvern, PA) and inulin (rafitline HP, Orafti, Malvern, PA). *B. infantis* ATCC 15697 was grown overnight in MRS and inoculated at 5% in modified MRS, replacing sodium acetate by sodium chloride (10 g/l peptone, 5 g/l yeast extract, 5 g/l sodium chloride, 2 g/l ammonium citrate, 0.2 g/l magnesium sulfate, 0.05 g/l manganese sulfate, 2 g/l dipotassium phosphate, 1 g/l tween 80, and 0.05% cysteine). Media was supplemented with equal amounts (2% w/v) of each carbon source mentioned above. The incubations were carried out at 37 °C in anaerobic chamber in triplicate (Coy Laboratory Products, Grass Lake, MI). After 48 h of incubation the final optical density was measured in a spectrophotometer at 600 nm (Shimadzu Scientific Instruments, Columbia MD), and the media was recovered by centrifuging at 12,000 × g for 10 min. Supernatants were analyzed using the L-lactate assay kit (Bioassay Systems, Hayward, CA), acetate assay kit (Bioassay Systems), and formate assay kit (Biovision, Milpitas, CA) according to the manufacturer instructions. For calculation of fermentation kinetic parameters, OD values were converted to dry weight in a ratio of 0.39 (Rossi et al., 2005), and these values were used with the amounts of SCFA in grams and initial concentration of each substrate (2 g/100 ml) to estimate the product yield of substrate ( $Y_{P/S}$ ), the biomass yield of substrate ( $Y_{X/S}$ ) and the product yield of biomass ( $Y_{P/X}$ ). Substrate consumption was assumed to be 100%.

## 3. Results

### 3.1. Consumption of GOS by *B. infantis* isolates

Twenty-two strains of *B. infantis* isolated from infant feces were studied *in vitro* for their ability to grow using 0.5% commercial GOS as the sole carbohydrate source. All isolates excepting SC97 showed a moderate to vigorous growth on GOS (Fig. 1). We also analyzed the supernatants of the fermentations in TLC plates (Fig. 2). All isolates were able to deplete the small amount of mono- and disaccharides found in commercial GOS, and DP3 was also consumed to a great extent. In general, disappearance of individual GOS with DP >3 was correlated with a higher final OD<sub>600</sub>, and conversely lower growth on GOS was related to a lack of consumption of larger GOS. For example, strains SC30, SC145 and UCD302 displayed the higher OD values on GOS and a noticeable reduction in all DP compared to the control with no bacteria added (Fig. 2). These results indicate that consumption of larger DP GOS is strain-




Fig. 1. In vitro growth of strains of *B. infantis* using 0.5% commercial GOS as the sole media carbon source.

3.2. Distribution of  $\beta$ -galactosidases in *B. infantis*

To provide molecular details on the consumption of GOS in *B. infantis*, we focused on the genome of *B. infantis* ATCC 15697, which contains five genes predicted to encode  $\beta$ -galactosidases, EC 3.2.1.23 (Table 1). Some of these genes are in the proximity of carbohydrate transporters (Supplementary Fig. 1), suggesting a co-regulated transcription. For example Blon\_0268 and Blon\_2334 are located next to sugar permeases, and Blon\_2416 is in a gene cluster containing an ABC transporter with affinity for oligosaccharides and a Glycosyl Hydrolase (GH) family 43. Blon\_2334 is part of the HMO cluster I (Sela et al., 2008), which contains several genes predicted to be important in metabolism of HMO in this bacterium. These enzymes belong to either GH2 or GH42, as defined by the Carbohydrate-Active Enzymes database ([www.cazy.org](http://www.cazy.org); (Cantarel et al., 2009)). The presence of these genes in some of the *B. infantis* isolates used in this study has been previously determined by comparative genome hybridization ((LoCascio et al., 2010); Supplementary Table 3). While Blon\_2016, Blon\_2123 and

Blon\_2334 were present in all the strains, Blon\_0268 was only found in strain UCD301 and Blon\_2416 was lacking in strains UCD298, UCD299 and UCD300, altogether with Blon\_2414, an upstream gene encoding a SBP induced by GOS in strain ATCC 15697.

3.3. Gene expression of  $\beta$ -galactosidases in *B. infantis* on GOS

A relative quantification of the expression levels for each  $\beta$ -galactosidase gene was performed on *B. infantis* grown to exponential phase using lactose, glucose, GOS or HMO as the sole carbon source. Results were normalized to gene expression levels of cells growing on lactose (Fig. 3). We considered significant a level of induction more than two fold, as previously determined to be comparable to proteomic data (Garrido et al., 2011). Two genes, Blon\_2123 and Blon\_2416, were repressed at least four fold in cells grown on glucose. In contrast, Blon\_0268 was induced eight fold during growth on glucose relative to lactose. When a pool of HMO was used as the sole carbon source, none of the enzymes was induced relative to lactose. However, Blon\_2016 and Blon\_2334 are




Fig. 2. Analysis of the consumption of GOS by *B. infantis* isolates by TLC. Supernatants represent strains in Fig. 1, and a control prepared under the same conditions but with no bacteria added was included (GOS lane). Plates were run in n-butanol-acetic acid-water 2:1:1 and developed with  $\alpha$ -naphthol. Numbers correspond to strains in Supplementary

**Table 1**  
Enzyme kinetic parameters and optimums for *B. infantis*  $\beta$ -galactosidases.

	Optimum pH	Optimum temperature	$K_m$ (mM)	$k_{cat}$ ( $s^{-1}$ )	$k_{cat}/K_m$ ( $s^{-1} M^{-1}$ )
Blon_0268	5.0	45 °C–55 °C	0.60	5.11	$8.50 \times 10^3$
Blon_2016	5.0	45 °C	0.70	1365.58	$1.94 \times 10^6$
Blon_2123	5.0–6.0	45 °C–55 °C	1.06	269.92	$2.5 \times 10^5$
Blon_2334	7.5	37 °C	0.29	420.04	$1.47 \times 10^6$
Blon_2416	5.0–6.5	45 °C	1.09	7.21	$6.58 \times 10^3$

constitutively expressed at high levels when *B. infantis* grows on HMO and lactose (Sela et al., 2008; Yoshida et al., 2012). Finally, growth on commercial GOS had the greatest impact on the transcription of *B. infantis*  $\beta$ -galactosidases, with Blon\_2334 induced over tenfold and Blon\_0268 and Blon\_2416 also induced over two fold by these oligosaccharides.

We also analyzed the expression levels for genes adjacent to Blon\_0268 and Blon\_2334 (Supplementary Fig. 2), encoding for transporters of the major facilitator superfamily. Even though the carbohydrate affinity of these transporters (Blon\_0267, Blon\_2331 and Blon\_2332) is unknown, their induction by GOS, as well as glucose (Blon\_0268), is suggestive that their affinities are related to these substrates.

### 3.4. Kinetic parameters of $\beta$ -galactosidases in *B. infantis*

In order to study some of the properties of these glycosyl hydrolases, they were cloned and expressed in *E. coli*, and purified with an N-terminal his-tag. ONPG was used for evaluating different kinetic parameters. Optimum pH values were relatively acidic for Blon\_0268 and Blon\_2016, and more neutral for the other three enzymes (Table 1). As observed with other  $\beta$ -galactosidases, the optimum temperature varied between 45 °C and 55 °C for all enzymes, except Blon\_2334 which showed the highest activity at 37 °C. Using these conditions, kinetic parameters were determined using ONPG. Turnover rates were the highest for Blon\_2016, and together with Blon\_2334, these glycosidases showed the greatest kinetic efficiency given by a  $k_{cat}/K_m$  ratio over  $1 \times 10^6 s^{-1} M^{-1}$ . These values are in agreement with those obtained by Yoshida et al. (2012), and they were 1000 times higher than the kinetic efficiencies observed for Blon\_0268 and Blon\_2416 on ONPG.

### 3.5. Relative affinities and substrate specificity of *B. infantis* $\beta$ -galactosidases


We also studied the activity of these enzymes on common  $\beta$ -galactosides. 4- and 6-galactobiose (Gal $\beta$ 1-4Gal and Gal $\beta$ 1-6Gal) and galactosyl-lactose (Gal $\beta$ 1-3Gal $\beta$ 1-4Glc) are common products in transglycosylation reactions (Gosling et al., 2010). Moreover, plant polysaccharides also contain these linkages as building blocks. As observed on TLC plates and considering the relative affinities for these substrates (Table 2), Blon\_0268 displayed an overall preference for 6' galactobiose (Fig. 4A, lanes 2–4; 9–11 and Fig. 4C, lane 3). Conversely, Blon\_2416 showed a preference for 4' galactobiose over galactosyl lactose (Fig. 4B lanes 6–7 and 13–14; Fig. 4C, lane 7). Blon\_2123 was only partially active on 6'galactobiose.

Blon\_2334 showed higher lactase activity compared to the other *B. infantis*  $\beta$ -galactosidases (Fig. 4A, lanes 20–22). Blon\_0268 and Blon\_2016 showed only a minor activity on this substrate (Fig. 4A, lanes 17–19 and Table 2). Blon\_2016 releases galactose very efficiently from type 1 HMO such as lacto-N-tetraose (LNT; Gal $\beta$ 1-3GlcNAc $\beta$ 1-3Gal $\beta$ 1-4Glc), and it had the highest enzymatic efficiency given by the  $k_{cat}/K_m$  ratio on ONPG (Table 1). The results presented in this study indicate that this enzyme can cleave other galactosyl linkages, such as those found in 4' and 6' galactobiose (Fig. 4C, lanes 2–3 and 8–9), 3' galactosyl lactose (Fig. 4C, lane 4), and GOS (Fig. 4D, lanes 4–5), displaying however a preference for LNT (Table 2).

Finally, after incubation of *B. infantis*  $\beta$ -galactosidases with commercial GOS for 1 h, we observed that four of them displayed significant hydrolytic activity on these prebiotics, as observed by an increase in time in the amount of galactose and glucose released from commercial GOS (Fig. 4A, lanes 23–30 and Fig. 4D).

### 3.6. Production of SCFA by *B. infantis*

Sugar metabolism in bifidobacteria differs from other bacterial metabolic pathways (Fushinobu, 2010) and is characterized by the presence of fructose-6-P phosphoketolase, an enzyme that generates acetyl-P and erythrose-4-P from fructose-6-P. This pathway, termed the “bifid shunt”, produces 2.5 mol of ATP per mole of glucose, as well as 3 mol of acetate and 2 mol of lactate that are



**Fig. 3.** Relative quantification of the gene expression of *B. infantis*  $\beta$ -galactosidases after logarithmic growth on the substrates indicated in the x-axis. Dashed lines indicate a two-

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.